Fortress Biotech, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2022 to Q3 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Fortress Biotech, Inc. annual/quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2022 to Q3 2023.
- Fortress Biotech, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2023 was -$10.6M, a 80.1% increase year-over-year.
- Fortress Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$154M, a 28% increase from 2022.
- Fortress Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$213M, a 29.9% decline from 2021.
- Fortress Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$164M, a 59.8% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)